Jobs
-
Emergent BioSolutions announced that it has signed an agreement to acquire marketing rights to Hikma Pharmaceuticals’ Kloxxado naloxone nasal spray in the US and Canada. Kloxxado, which delivers an 8 mg dose, was approved by the… Read more . . .
-
Vistagen has announced the initiation of a Phase 2 repeat dose study of fasedienol nasal spray, which the company is developing for the treatment of social anxiety disorder. The Phase 3 PALISADE-3 and PALISADE-4 trials… Read more . . .
-
Orexo has announced topline results from its OX640-002 PK/PD study of OX640 intranasal dry powder epinephrine in people with allergic rhinitis. According to the company, the study, which was initiated in October 2024, demonstrated that… Read more . . .
-
Lactose supplier DFE Pharma has announced the availability of analytical services for dry powder inhaler formulations at its Closer to the Formulator (C2F) Center of Excellence in Hyderabad, India, in response to growing demand. According to DFE,… Read more . . .
-
Spray drying experts Lonza will develop spray dried dry powder formulations for delivery by Iconovo‘s ICOone Nasal device, the companies announced. According to the announcement, the collaboration involves “a reformulated substance for obesity.” In May 2024,… Read more . . .
-
A Texas-based company founded as Lung Therapeutics in 2013 and acquired by Aileron Therapeutics in 2023 announced that it has now changed its name to Rein Therapeutics. Lung Therapeutics spun off TFF Pharmaceuticals in 2018 to develop dry… Read more . . .
-
Irish biopharm company GH Research said that it has completed inhalation toxicology studies of GH001 inhaled mebufotenin (5-MeO-DMT) necessary to address the FDA’s 2023 clinical hold on an IND that the company had submitted for a… Read more . . .
-
Intranasal vaccine developer Leyden Laboratories announced the closing of a $70 million funding round, with proceeds going to support development of prophylactic nasal sprays based on the company’s “Mucosal Protection Platform.” Leyden Labs, which initiated… Read more . . .
-
Aer Therapeutics has announced the initiation of the AER-01-002 Phase 2a proof-of-concept study of nebulized fexlamose (formerly AER-01) in COPD patients with high mucus plug scores. The trial is expected to enroll 100 patients with… Read more . . .
-
Qnovia (formerly Respira Technologies) has announced the initiation of a Phase 1 PK study of its QN-01 inhaled nicotine, which is delivered via the company’s RespiRx vibrating mesh inhaler. In October 2024, Qnovia announced that the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland